N/A
Completed N=62
Effects of Deep Brain Stimulation on Motor, Mood, and Cognitive Symptoms in Parkinson's Disease
Source: ClinicalTrials.gov NCT00360009 ↗Enrolled (actual)
62
Serious AEs
22.6%
Results posted
Feb 2010
Primary outcomePrimary: Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State — 5.3; -0.1 T-score
Summary
The purpose of this trial is to study the mood and cognitive effects of deep brain stimulation in Parkinson's disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mean T-score of Visual Analogue Mood Scales (VAMS) Angry State |
5.3; -0.1 | — |
| PRIMARY Change in Visual Analogue Mood Scales (VAMS) Afraid State |
1.3; -2.2 | — |
| PRIMARY Change in Visual Analogue Mood Scales (VAMS) Confused State |
5.7; 1.3 | — |
| PRIMARY Change in Visual Analogue Mood Scales (VAMS) Energetic State |
-1.4; 2.0 | — |
| PRIMARY Change in Visual Analogue Mood Scales (VAMS) Happy State |
2.9; 5.0 | — |
| PRIMARY Change in Visual Analogue Mood Scales (VAMS) Sad State |
-2.4; -1.0 | — |
| PRIMARY Change in Visual Analogue Mood Scales (VAMS) Tense State |
-2.0; -8.5 | — |
| PRIMARY Change in Visual Analogue Mood Scales (VAMS) Tired State |
-8.5; -2.0 | — |
| SECONDARY Change in Spielberger State-Trait Anxiety Inventory (STAI) |
-3.3; 0.3 | — |
| SECONDARY Change in Beck Depression Inventory (BDI) |
-2.8; -4.6 | — |
| SECONDARY Change in Letter Fluency Tasks (LFT) |
-5.6; 0.3 | — |
Eligibility Criteria
Inclusion Criteria
- Intractable, disabling PD with motor fluctuations, dyskinesias, or freezing episodes
- Age between 30-75 years
- Unsatisfactory clinical response to maximal medical management (with trials of both higher and lower doses of anti-Parkinsonian drugs)
- A stable and optimal medical regimen of anti-Parkinsonian drug therapy for at least three months prior to surgery
- Patients must be right-handed to be included in the study since mood and cognition are being analyzed and right hemisphere dominant patients could confound the results.
Exclusion Criteria
- Clinically significant medical disease that would increase risk of developing pre- or postoperative complications (e.g., significant cardiac or pulmonary disease, uncontrolled hypertension)
- Evidence of secondary or atypical parkinsonism as suggested by the presence of any of the following: 1) history of stroke(s), 2) exposure to toxins or neuroleptics, 3) history of encephalitis, 4) neurological signs of upper motor neuron disease, cerebellar involvement, supranuclear gaze palsy, or significant orthostatic hypotension
- MRI scan with significant evidence of brain atrophy or other abnormalities (e.g., lacunar infarcts or iron deposits in the putamen)
- The Mattis Dementia Rating Scale will be used to assess the level of intellectual function and patients will be excluded with scores reflecting clinical dementia
- A major psychiatric disorder on the Structured Clinical Interview for DSM-IV (SCID-IV).
Data sourced from ClinicalTrials.gov (NCT00360009). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.